Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026)
Zoetis (ZTS) posted quarterly Total Non-Current Liabilities of $11.6 billion for Q1 2026, up 26.99% year-over-year from $9.2 billion in Q1 2025, and down 1.56% quarter-over-quarter from $11.8 billion in Q4 2025.
Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Total Non-Current Liabilities for 15 consecutive years, with $11.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 26.99% year-over-year to $11.6 billion; the TTM figure through Mar 2026 stood at $11.6 billion (up 26.99% YoY), while the FY2025 annual figure was $11.8 billion, up 28.6% from the prior year.
- Total Non-Current Liabilities retreated to $11.6 billion in Q1 2026 per ZTS's latest filing, from $11.8 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $11.8 billion in Q4 2025 and bottomed at $8.8 billion in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $9.4 billion across 5 years, with a median of $9.1 billion in 2023.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities decreased 11.75% — and 2025, when it climbed 28.6%.
- Zoetis' Total Non-Current Liabilities stood at $10.3 billion in 2022, then dropped by 11.75% to $9.1 billion in 2023, then rose by 1.51% to $9.2 billion in 2024, then gained by 28.6% to $11.8 billion in 2025, then decreased by 1.56% to $11.6 billion in 2026.
- Business Quant data shows ZTS's Total Non-Current Liabilities at $11.6 billion in Q1 2026, $11.8 billion in Q4 2025, and $9.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.64 Bn |
| Mar 31, 2026 | 11.64 Bn |
| Dec 31, 2025 | 11.83 Bn |
| Sep 30, 2025 | 9.50 Bn |
| Jun 30, 2025 | 9.23 Bn |
| Mar 31, 2025 | 9.17 Bn |
| Dec 31, 2024 | 9.20 Bn |
| Sep 30, 2024 | 8.85 Bn |
| Jun 30, 2024 | 8.98 Bn |
| Mar 31, 2024 | 9.07 Bn |
| Dec 31, 2023 | 9.06 Bn |
| Sep 30, 2023 | 8.77 Bn |
| Jun 30, 2023 | 8.91 Bn |
| Mar 31, 2023 | 9.05 Bn |
| Dec 31, 2022 | 10.26 Bn |
| Sep 30, 2022 | 8.77 Bn |
| Jun 30, 2022 | 8.96 Bn |
| Mar 31, 2022 | 8.96 Bn |
| Dec 31, 2021 | 9.12 Bn |
| Sep 30, 2021 | 8.77 Bn |